Pfizer (PFE) Gross Profit (2009 - 2026)

Pfizer has disclosed Gross Profit across 18 years of filings, most recently posting -$1.2 billion for Q1 2026.

• In Q1 2026, Gross Profit fell 65.16% year-over-year to -$1.2 billion; the TTM figure through Mar 2026 stood at $7.7 billion (down 51.68% YoY), while the FY2025 annual figure was $46.5 billion, up 591.51% from the prior year.
• Gross Profit eased to -$1.2 billion in Q1 2026, from $12.3 billion in the prior quarter.
• Over the last five years, Gross Profit for PFE reached as high as $19.1 billion in Q3 2022 and fell as low as -$7.6 billion in Q4 2023.
• The 5-year median for Gross Profit is -$732.0 million (2025), against an average of $4.1 billion.
• Annual changes were most pronounced in 2023 — Gross Profit plunged 146.0% — and 2024, when it jumped 3845.85%.
• A 5-year view of Gross Profit shows it stood at $16.6 billion in 2022, then slumped by 124.91% to -$4.1 billion in 2023, then decreased by 16.76% to -$4.8 billion in 2024, then jumped by 354.82% to $12.3 billion in 2025, then plunged by 109.84% to -$1.2 billion in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered -$1.2 billion, $12.3 billion, and -$1.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.